Study S003324

A Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Ic Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06371326
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 28
Start: 2023-11-21
Primary completion: 2024-04-15
Lead sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Conditions: Overweight or Obesity
Interventions: DRUG:ZT002 Injection; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Safety and tolerability of a multiple escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in MAD Cohorts. Number of participants with treatment-emergent adverse events. [up to 270 days]
Safety and tolerability of a multiple escalation dose of ZT002 through the incidence severity of serious adverse events in MAD Cohorts. Number of participants with serious adverse events. [up to 270 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.